ReviewThe Lancet. Neurology2020
The characterisation of subjective cognitive decline.
6 registry-linked trialsAbstract readReview
In one paragraph
Review in The Lancet. Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 749 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
749citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Renji Alzheimer's Disease Neuroimaging Cohort Study
NCT06588946 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation
The Effect of Exogenous Β-OHB Supplementation on Cerebral Blood Flow and Functional Brain Characteristics in Adults with Subjective Cognitive Decline
NCT07284316 phase2 / phase3active not recruitingnot on this mapstarted 2025, after this paper: background citation
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance: A Randomized Clinical Trial
Physiological Effect of Non-invasive Photobiomodulation on Cognition and Mood in Older Adults With Subjective Cognitive Impairment
Implementation of a Brain Health Service for Personalized Stratification and Prevention of Dementia Risk: The B-HEALTH Project
Development of Digital Solutions for the Prediction of the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors (PrevAI)
Who cites it
749 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Electroencephalography in Subjective Cognitive Decline and Mild Cognitive Impairment: Systematic Review of Biomarkers, Classification, and Prognostic Evidence.Journal of medical Internet research · 2026Pooled it
- Chronic pain and risk of cognitive impairment: a meta-analysis of longitudinal cohort studies.Translational psychiatry · 2026Pooled it
- Efficacy and safety of tACS in older adults with cognitive impairment: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Diagnostic utility of speech-based biomarkers in mild cognitive impairment: a systematic review and meta-analysis.Age and ageing · 2025Pooled it
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Objective Criteria for Subtle Cognitive Decline in Aging and Preclinical Alzheimer Disease: A Systematic Review.Neurology · 2025Pooled it
- Trial
- Neurobiological markers across joint profiles of subjective cognitive decline and objective cognitive function in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Baseline predictors of neurophysiological response to combined physical and cognitive training in older adults with subjective cognitive decline.BMC geriatrics · 2026Trial
- [Differential effects of computerized cognitive stimulation versus stimulating leisure activities on mood and global cognition in adults with subjective and mild cognitive impairment: A randomized controlled trial].Anales del sistema sanitario de Navarra · 2025Trial
- A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study).The journal of prevention of Alzheimer's disease · 2025Trial
- Cortical thickness signature of early-onset Alzheimer's disease across clinical stages and A/T1 biomarker profiles.Journal of neurology · 2026Article
- Subjective Cognitive Complaints and Hearing Loss in Older Adults-A Cross-Sectional Study on the Possible Association.Scandinavian journal of psychology · 2026Article
- Dementia risk factors and biomarkers in subjective cognitive decline: real world evidence from the monza brain health service.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Cognitive Aging Patterns in Autism: Parallel, Accelerated, or Safeguarded?Journal of autism and developmental disorders · 2026Article
- Separating ECog scale-score information from dyad availability: observation-process contributions to dyadic prediction of cognitive impairment in ADNI.Research square · 2026Article
- White matter microstructural alterations associated with type-2 diabetes mellitus and mild cognitive impairment.Brain imaging and behavior · 2026Article
- Gender bias in the diagnosis of Alzheimer's Disease.Research square · 2026Article
- Comparative Prognostic Performance of Hippocampal Volume and Plasma Biomarkers in Amyloid-Negative Subjective Cognitive Decline: A Four-Year Follow-up.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Unmasking preclinical Alzheimer's pathology: auditory distraction cost and occupational reserve jointly discriminate amyloid positivity in subjective cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
689 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors.
Frank JessenDepartment of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. Electronic address: frank.jessen@uk-koeln.de.
Rebecca E AmariglioCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital and Department of Neurology Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rachel F BuckleyDepartment of Neurology, Brigham and Women's Hospital and Department of Neurology Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Florey Institute, University of Melbourne, Parkville, VIC, Australia; Melbourne School of Psychological Sciences, University of Melbourne, Parkville, VIC, Australia.
Wiesje M van der FlierAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; Department of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Ying HanDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China; Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China; Beijing Institute of Geriatrics, Beijing, China; National Clinical Research Center for Geriatric Disorders, Beijing, China.
José Luis MolinuevoAlzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Barcelona, Spain; Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.
Laura RabinDepartment of Psychology, Brooklyn College and The Graduate Center of CUNY, Brooklyn, NY, USA; Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA.
Dorene M RentzCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital and Department of Neurology Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Octavio Rodriguez-GomezAlzheimer Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
Andrew J SaykinDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Sietske A M SikkesDepartment of Neurology, Brigham and Women's Hospital and Department of Neurology Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; Department of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Colette M SmartDepartment of Psychology, University of Victoria, Victoria, BC, Canada; Institute on Aging & Lifelong Health, University of Victoria, Victoria, BC, Canada.
Steffen WolfsgruberGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Michael WagnerGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; Department of Neurodegeneration and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MResearch Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI GHETTI, BERNARDINO FRANCESCO · 1991 to 2020
$37.3MMemory Circuitry in MCI and Early Alzheimer’s Disease Prodrome: Molecular DriversR01AG019771 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 2001 to 2021
$6.9MCharacterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's diseaseR01AG058825 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AMARIGLIO, REBECCA E · 2019 to 2024
$4.0MOptimizing measures of subjective and objective decline in preclinical ADK23AG044431 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AMARIGLIO, REBECCA E · 2014 to 2018
$742kNIA NIH HHS K23 AG044431NIA NIH HHS P30 AG010133NIA NIH HHS R01 AG019771NIA NIH HHS R01 AG058825NIA NIH HHS U01 AG024904
Abstract
A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term subjective cognitive decline (SCD) was conceived in 2014 to describe this condition. Epidemiological data provide evidence that the risk for mild cognitive impairment and dementia is increased in individuals with SCD. However, the majority of individuals with SCD will not show progressive cognitive decline. An individually tailored diagnostic process might be reasonable to identify or exclude underlying medical conditions in an individual with SCD who actively seeks medical help. An increasing number of studies are investigating the link between SCD and the very early stages of Alzheimer's disease and other neurodegenerative diseases.
Indexed as
Alzheimer DiseaseBrainCognitionCognitive DysfunctionDiagnostic Self EvaluationDisease ProgressionHumansNeuropsychological Tests
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05433363ClinicalTrials.gov
NCT06588946ClinicalTrials.gov
NCT07284316ClinicalTrials.gov
NCT07445945ClinicalTrials.gov
NCT07698431ClinicalTrials.gov
NCT07731191ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.